Valuation: GENFIT

Market Cap 694M 804M 651M 593M 1.12B 76.9B 1.13B 7.64B 2.99B 38.53B 3.02B 2.95B 128B P/E 2026 *
35.8x
P/E 2027 * 92.2x
Enterprise Value 643M 745M 603M 550M 1.03B 71.24B 1.05B 7.07B 2.77B 35.69B 2.8B 2.74B 119B EV / Sales 2026 *
6.42x
EV / Sales 2027 * 5.06x
Free-Float
86.89%
Yield 2026 *
-
Yield 2027 * -
1 day+48.37%
1 month+48.37%
3 months+68.43%
6 months+98.63%
Current year+165.83%
1 month 15.95
Extreme 15.95
15.95
Current year 7.26
Extreme 7.26
15.95
1 year 4.14
Extreme 4.14
15.95
3 years 2.95
Extreme 2.95
15.95
5 years 2.95
Extreme 2.95
15.95
10 years 0
Extreme 0
36.86
Manager TitleAgeSince
Chief Executive Officer 58 15/09/2019
Director of Finance/CFO 52 21/04/2021
Chief Tech/Sci/R&D Officer - 26/11/2025
Director TitleAgeSince
Chairman 70 15/06/2017
Director/Board Member 54 14/09/1999
Director/Board Member 58 15/06/2017
Change 5-day change 1-year change 3-year change Capi.($)
+48.37%-.--% - - 804M
-0.11%-1.70%+1.76%+19.86% 48.84B
+0.11%+3.85%+485.62%+620.66% 45.44B
+1.00%+2.19%+14.97%+90.17% 41.22B
+0.93%+0.54%+27.33%+14.57% 39.71B
-0.50%0.00%+20.60%+60.49% 32.6B
+1.19%-1.65% - - 16.25B
-0.95%-1.65%+28.64%+138.50% 16.67B
-0.09%0.00%+3.80%+29.59% 14.08B
-0.10%+1.74%+82.76%+44.24% 13.68B
Average +5.10%+0.02%+83.19%+127.26% 29.83B
Weighted average by Cap. +0.48%+0.03%+103.83%+153.70%

Financials

2026 *2027 *
Net sales 100M 116M 94M 85.62M 161M 11.1B 163M 1.1B 432M 5.56B 436M 426M 18.49B 124M 144M 116M 106M 199M 13.74B 202M 1.36B 535M 6.88B 539M 528M 22.9B
Net income 22.88M 26.5M 21.46M 19.55M 36.76M 2.53B 37.27M 252M 98.6M 1.27B 99.49M 97.34M 4.22B 6.8M 7.88M 6.38M 5.81M 10.93M 753M 11.08M 74.78M 29.31M 377M 29.57M 28.93M 1.26B
Net Debt -51.12M -59.21M -47.96M -43.68M -82.13M -5.66B -83.27M -562M -220M -2.84B -222M -217M -9.43B -66.17M -76.65M -62.08M -56.54M -106M -7.33B -108M -728M -285M -3.67B -288M -282M -12.21B
Logo GENFIT
GENFIT is a biopharmaceutical company in late-stage development focused on the discovery and development of innovative therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, in particular due to a lack of approved treatments. GENFIT is a leading innovator in the field of nuclear receptor-based drug discovery with a rich history and a solid scientific heritage spanning nearly two decades. The company has offices in Lille, Paris, Zurich and Cambridge, MA (USA).
Employees
161
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
13.88EUR
Average target price
15.90EUR
Spread / Average Target
+14.55%

Quarterly revenue - Rate of surprise